Investigational drug · Phase 2
zetomipzomib
Also called: KZR-616, zetomipzomib in open-label extension
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Autoimmune Hepatitis.
Phase 2Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "zetomipzomib"
First trial start
2023
May 23, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "zetomipzomib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Autoimmune Hepatitis
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "zetomipzomib" as an intervention, largest first.
Kezar Life Sciences, Inc.Industry
NCT05781750 · 84 participants · Start Nov 3, 2023 · Primary completion Nov 8, 2024
Drug: zetomipzomib; placebo · For: Lupus Nephritis
Sites: Lake Charles, Louisiana; East Providence, Rhode Island; Colleyville, Texas · 50 sites in all
Kezar Life Sciences, Inc.Industry
NCT03393013 · 69 participants · Start Feb 20, 2018 · Primary completion Aug 4, 2022
Drug: KZR-616 · For: Lupus Nephritis; Systemic Lupus Erythematosus
Sites: Los Angeles, California; Upland, California; Miami, Florida · 36 sites in all
Kezar Life Sciences, Inc.Industry
NCT04033926 · 25 participants · Start Jan 14, 2020 · Primary completion Apr 6, 2022
Drug: KZR-616; Placebo · For: Polymyositis; Dermatomyositis
Sites: Beverly Hills, California; Orange, California; Miami, Florida · 14 sites in all
Kezar Life Sciences, Inc.Industry
NCT05569759 · 24 participants · Start May 23, 2023 · Primary completion Apr 30, 2025
Drug: zetomipzomib; placebo and 1 more · For: Autoimmune Hepatitis
Sites: Phoenix, Arizona; Los Angeles, California; Redwood City, California · 24 sites in all
Kezar Life Sciences, Inc.Industry
NCT04628936 · 18 participants · Start Nov 4, 2020 · Primary completion Mar 10, 2023
Drug: KZR-616 · For: Polymyositis; Dermatomyositis
Sites: Beverly Hills, California; Orange, California; Miami, Florida · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety and efficacy of zetomipzomib in relapsed or insufficiently responding autoimmune hepatitis: Results from the randomized, double-blind, placebo-controlled, phase 2a PORTOLA study and open-label extension.
Lammert CS, Weinberg EM, Sclair SN, et al. · Hepatology 2026
- α-Aminoboronic Acid Moieties in Boro Dipeptides Modulate Proteasome Subunit Selectivity and Provide Access to Compounds with Potent Anticancer and Anti-Inflammatory Activity.
Stra¡ek Benedik N, terman A, Smrdel L, et al. · J Med Chem 2025
- Immunoproteasomes in Skeletal Muscle Pathologies: Emerging Roles, Conflicting Evidence, and Future Directions.
Kalinkovich A, Livshits G · Cells 2025
- Targeting the ubiquitin-proteasome pathway in systemic lupus erythematosus.
Mok CC · Expert Rev Clin Immunol 2025
- Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses.
Muchamuel T, Fan RA, Anderl JL, et al. · Front Immunol 2023
- Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome.
Del Rio Oliva M, Kirk CJ, Groettrup M, et al. · Eur J Immunol 2022
Also in development for Autoimmune Hepatitis
- HR19042Phase 21 trial
Jiangsu HengRui Medicine Co., Ltd. · Autoimmune Hepatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.